These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 29359667)
1. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach. Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667 [TBL] [Abstract][Full Text] [Related]
2. Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312 [TBL] [Abstract][Full Text] [Related]
3. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology. Gajera BY; Shah DA; Dave RH Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724 [TBL] [Abstract][Full Text] [Related]
4. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes. Patel PJ; Gajera BY; Dave RH Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique. Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039 [TBL] [Abstract][Full Text] [Related]
6. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide. Sahu BP; Das MK Acta Pol Pharm; 2014; 71(1):129-37. PubMed ID: 24779201 [TBL] [Abstract][Full Text] [Related]
7. Quality by design approach to understand the process of nanosuspension preparation. Verma S; Lan Y; Gokhale R; Burgess DJ Int J Pharm; 2009 Jul; 377(1-2):185-98. PubMed ID: 19446617 [TBL] [Abstract][Full Text] [Related]
8. Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation. Alshweiat A; Katona G; Csóka I; Ambrus R Eur J Pharm Sci; 2018 Sep; 122():94-104. PubMed ID: 29908301 [TBL] [Abstract][Full Text] [Related]
9. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design. Kassem MAA; ElMeshad AN; Fares AR AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564 [TBL] [Abstract][Full Text] [Related]
10. Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach. Kuk DH; Ha ES; Ha DH; Sim WY; Lee SK; Jeong JS; Kim JS; Baek IH; Park H; Choi DH; Yoo JW; Jeong SH; Hwang SJ; Kim MS Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31861173 [TBL] [Abstract][Full Text] [Related]
11. [Preparation and characterization of icariin nanosuspension and lyophilized powder]. Hui-Rong XI; Hui-Ping MA; Ke-Ming C; Xiao-Shuan L Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):4902-4908. PubMed ID: 33350263 [TBL] [Abstract][Full Text] [Related]
12. Development of Atovaquone Nanosuspension: Quality by Design Approach. Kakade P; Gite S; Patravale V Curr Drug Deliv; 2020; 17(2):112-125. PubMed ID: 31880260 [TBL] [Abstract][Full Text] [Related]
13. A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound. Jakubowska E; Milanowski B; Lulek J Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830298 [TBL] [Abstract][Full Text] [Related]
14. Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment. Shekhawat P; Pokharkar V Int J Pharm; 2019 Aug; 567():118415. PubMed ID: 31175989 [TBL] [Abstract][Full Text] [Related]
15. Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design. Rao MR; Bajaj A Drug Res (Stuttg); 2014 Dec; 64(12):663-7. PubMed ID: 24549965 [TBL] [Abstract][Full Text] [Related]
16. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation. Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401 [TBL] [Abstract][Full Text] [Related]
17. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation. Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130 [TBL] [Abstract][Full Text] [Related]
18. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach. Karakucuk A; Celebi N; Teksin ZS Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836 [TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability. Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526 [TBL] [Abstract][Full Text] [Related]
20. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability. Parmar K; Shah J Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]